secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104569
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences submits cytisinicline NDA to FDA; cash position $55.4M
----------------------------------------------------------------------------

- NDA submitted to FDA in June 2025 for cytisinicline as smoking cessation treatment in adults.
- Raised $49.3M gross from underwritten public offering in June-July 2025; expects runway into H2 2026.
- Partnered with Omnicom for integrated launch strategy, reducing internal commercial buildout costs.
- ORCA-OL safety requirements met: >300 subjects with ≥6 months, >100 with ≥1 year cumulative exposure.
- Q2 2025 net loss $12.7M; operating expenses $12.6M; cash & securities $55.4M as of June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017025104569/0000950170-25-104569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017025104569/achv-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer